A MedCity News report reviewed emerging genetic screening tools that predict rare but deadly adverse reactions to common cancer drugs and improve drug selection. Despite mounting evidence of clinical utility and published guidelines for pharmacogenomic testing, adoption in oncology practice remains limited, the article found. Barriers include workflow integration, reimbursement uncertainty and limited provider education. The piece cites clinicians and implementation studies to argue for system‑level changes—electronic decision support, payer coverage and laboratory capacity—to translate predictive screening into routine oncology care.